Becton Dickinson (BDX) Following Its Veritor Shift And Index Changes Looks Undervalued

Becton Dickinson (BDX) has drawn attention after requesting that the FDA revoke the Emergency Use Authorization for its BD Veritor SARS-CoV-2 test, while also being reshuffled across the Russell Midcap and Russell Top 200 equity benchmarks.

See our latest analysis for Becton Dickinson.

Index reshuffles and the end of the BD Veritor EUA have come alongside mixed performance for Becton Dickinson. Recent momentum has firmed, with the 7 day share price return at 3.28% and the 1 year total shareholder return at 16.69%, despite a year to date share price decline of 19.82%.

If you are looking beyond Becton Dickinson in healthcare, this may be a good moment to scan for other opportunities in medical and diagnostics technology through the 40 healthcare AI stocks

Becton Dickinson still looks like a sizeable, diversified healthcare business, yet its recent share price swings and index reshuffle raise a simpler question: are you paying a fair price for that quality today?

Most Popular Narrative: 13.8% Undervalued

Becton Dickinson last closed at $156.30, while the most followed narrative places fair value closer to $181.23, framing the recent moves as a discount rather than a premium.

The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue). This is expected to enable higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.

Read the complete narrative.

Want to see what sits underneath that valuation gap? The narrative leans heavily on earnings power, margin uplift, and a richer profit multiple than the sector. The full story connects those moving parts into one pricing blueprint.

Result: Fair Value of $181.23 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Becton Dickinson narrative could be knocked off course if trade and tariff pressures weigh on margins, or if the Biosciences and Diagnostics separation proves more disruptive than planned.

Find out about the key risks to this Becton Dickinson narrative.

Next Steps

Given the mixed signals around Becton Dickinson, does the overall sentiment feel balanced enough for your comfort, or too finely poised to ignore? Take a moment to review the underlying data, weigh both the concerns and potential upsides, then ground your own stance in the 5 key rewards and 2 important warning signs

Looking for more investment ideas beyond Becton Dickinson?

If Becton Dickinson has sharpened your focus on quality and valuation, do not stop here. Broaden your watchlist now before the next set of opportunities moves without you.

• Target income potential with companies screened for resilient payouts by reviewing the 9 dividend fortresses
• Spot potential value gaps by scanning companies that combine quality fundamentals with attractive valuations through the 45 high quality undervalued stocks
• Prioritise resilience by focusing on companies with stronger balance sheets and steadier financial profiles using the solid balance sheet and fundamentals stocks screener (47 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.